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Activation of the 
phosphatidylcholine to 
Lysophosphatidylcholine pathway 
Is Associated with osteoarthritis 
Knee Cartilage Volume Loss over 
time
Guangju Zhai1, Jean-pierre pelletier2, Ming Liu1, Dawn Aitken3, edward Randell4, 
proton Rahman5, Graeme Jones3 & Johanne Martel-pelletier2
To identify serum biomarker(s) for predicting knee cartilage volume loss over time, we studied 139 
knee osteoarthritis (OA) patients from a previous 24-month clinical trial cohort. Targeted metabolomic 
profiling was performed on serum collected at baseline. The pairwise metabolite ratios as proxies 
for enzymatic reaction were calculated and used in the analysis. Cartilage volume loss between 
baseline and 24 months was assessed quantitatively by magnetic resonance imaging (MRI). Data 
revealed an association between the serum ratio of lysophosphatidylcholine 18:2 (lysoPC 18:2) 
to phosphatidylcholine 44:3 (PC44:3) and the cartilage volume loss in the lateral compartment 
(β = −0.21 ± 0.04, p = 8.53*10−7) and with joint degradation markers, CoMp (r = 0.32, p = 0.0002) and 
MMP1 (r = 0.26, p = 0.002). The significance remained after adjustment for age, sex, BMI, diabetes, 
hypertension, dyslipidemia, and the treatment taken in the original study. As the ratio indicated the 
over activation of the conversion pathway of pC to lysopC catalyzed by phospholipase A2 (pLA2), we 
assessed and found that a specific PLA2, pLA2G5, was significantly increased in human OA cartilage 
and synovial membrane (85% and 19% respectively, both p < 0.04) compared to controls, and its 
overexpression correlated with IL-6 (r = 0.63, p = 0.0008). Our data suggest that the serum lysoPC 18:2 
to PC44:3 ratio is highly associated with a greater risk of cartilage volume loss of the knee and warrants 
further investigation in an independent cohort.
Osteoarthritis (OA) is the most prevalent joint disease in the world. It affects about 10% of the population glob-
ally and about half of the population aged 60 years or older1. The disease results in joint pain and disability2, and 
imposes a significant socioeconomic burden on society with an aggregate cost of ~2.5% of gross domestic prod-
uct3. The disease can be difficult to define as it has an insidious onset, and clinically represents a heterogeneous 
group of diseases. Hence, OA evolution can be slow and last many years, but could progress rapidly4–6, leading to 
the need for total joint replacement therapy. At present, OA diagnosis occurs mainly at a moderate-to-severe stage 
of the disease and often only where the destruction of the joint tissue has reached an advanced stage. Clinical 
parameters do not provide sufficient information to make a good prediction or prognosis. To achieve prognosis, 
one should be able to quickly have accurate results. One means is the use of serum biomarkers which will help 
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clinical practice by selecting patients who will best benefit from specific therapeutic interventions. However, to 
date, no biomarker has been reported to be useful as a prognostic test in individual patients.
Recent development in metabolomics and its application to the study of OA are promising7. Several small 
studies have identified certain metabolic pathways that play a role in OA8,9. Among them, the arginine and pro-
line metabolic pathway appears to be one of the main pathways identified to be associated with knee OA10,11. 
Consistent with these reports, we and others have found that a lower plasma free arginine level was associated 
with end-stage knee OA in studies with a relatively large sample size12,13. Further, our group found that total lys-
ophosphatidylcholines (lysoPCs) to phosphatidylcholines (PCs) ratio was associated with knee OA risk; people 
with higher lysoPCs to PCs ratio at baseline had a 2.3 times greater risk of undergoing total joint replacement sur-
gery in 10 year follow-up14. Such ratio was also found to be associated with early OA15, but it is unclear whether 
these metabolic markers are associated with OA progression. We therefore undertook to identify novel metabolic 
markers using a previous clinical trial cohort16 and a targeted metabolomics approach on knee OA disease pro-
gression. The disease progression was measured by the percentage of cartilage volume loss as assessed by mag-
netic resonance imaging (MRI), which has been demonstrated as being one of the best markers of OA disease 
progression and outcome as well as the need for total knee replacement (the hard outcome in knee OA) as shown 
in several studies (refer to the review17).
Results
Table 1 presents the descriptive characteristics of the study population. As originally reported16, there was 
no difference in age, sex, BMI, and baseline lateral and medial cartilage volumes between the two treatment 
arms. However, the cartilage loss at 24 months was significantly reduced with licofelone treatment compared to 
naproxen treatment, at the lateral compartment (p = 0.02). The same trend was seen for the medial compartment 
though it did not reach statistical significance.
Association of lysoPC 18:2 to PC44:3 ratio with cartilage volume loss. One hundred and fifty-two 
(152) metabolites standardized by Z-score were used for pair-wise ratios. Unadjusted analyses showed that, based 
on the adjusted pre-defined significance level (p = 2.3*10−6), the lysophosphatidylcholine with 18 carbons and 
2 double bonds (lysoPC 18:2) to phosphatidylcholine with 44 carbons and 3 double bonds (PC 44:3) was signifi-
cantly associated with the percentage of the lateral cartilage loss (p = 8.5*10−7) (Table 2). The lateral cartilage vol-
ume was reduced by 0.21% (95% CI −0.30%; −0.13%) per unit increase for the ratio. The significance remained 
(p = 4.5*10−6) after adjusting for covariates including age, sex, BMI, diabetes, hypertension, dyslipidemia, and 
treatments taken in the original study (Table 2). Although not reaching the pre-defined significance level, the 
second and third most potentially associated metabolite ratios (Table 2) lysoPC 18:1 to PC 44:3 and glutamine 
to PC 44:3 were also found to be highly correlated with lysoPC 18:2 to PC 44:3 (r = 0.79, p = 2.2*10−16; r = 0.49, 
p = 8.9*10−11).
Variables
Licofelone group
(n = 69)
Naproxen group
(n = 70)
Age (yrs) 61 ± 9 61 ± 8
Sex (% female) 74% 61%
BMI (kg/m2) 32.3 ± 5.8 31.2 ± 5.7
Lateral cartilage volume at baseline (mm3) 6095.5 ± 1594.7 6364.1 ± 1822.0
Lateral cartilage volume changes at 24 months (%) −4.70 ± 4.16% −6.40 ± 4.14%
Medial cartilage volume at baseline (mm3) 5523.0 ± 1503.3 5690.0 ± 1640.0
Medial cartilage volume changes at 24 months (%) −7.58 ± 5.15% −8.25 ± 6.01%
Table 1. Descriptive characteristics of the study population. Results are shown as mean ± SD except for sex 
which was shown as percentage for females.
Metabolite ratios
Unadjusted* Adjusted**
β (95% CI) P value β (95% CI) P value
LysoPC 18:2/PC44:3 −0.21 (−0.30; −0.13) 8.5*10−7 −0.18 (−0.27; −0.10) 4.5*10−6
LysoPC18:1/PC44:3 −0.28 (−0.40; −0.16) 1.3*10−5 −0.25 (−0.37; −0.13) 1.5*10−5
Glutamine/PC44:3 −0.28 (−0.40; −0.16) 1.9*10−5 −0.28 (−0.40; −0.16) 3.6*10−6
Methionine/proline 0.09 (0.05; 0.12) 3.0*10−5 0.07 (0.04; 0.11) 6.9*10−5
Table 2. The top four metabolite ratios that associated with the percentage of the lateral cartilage volume loss 
at 24 months. *Associations were tested by using linear regression model. **Covariates including age, sex, BMI, 
diabetes, hypertension, dyslipidemia, and treatment were included in the multivariable linear regression model. 
β stands for percentage change in cartilage volume at 24 months per unit increase for a given ratio. For example, 
lateral cartilage volume was reduced by 0.21% at 24 months for one unit increase of the ratio of the Z-scores of 
lysoPC 18:2 and PC 44:3. LysoPC 18:2: lysophosphatidylcholine with 18 carbons and 2 double bonds; PC44:3: 
phosphatidylcholine with 44 carbons and 3 double bonds; lysoPC 18:1: lysophosphatidylcholine with 18 
carbons and 1 double bond.
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For the medial compartment, four metabolite ratios related to phosphatidylcholine metabolism demonstrated 
high significance associated with this compartment’s cartilage volume loss, although their significance did not 
reach the adjusted pre-defined level (Table 3).
Arginine, which was previously reported to be associated with knee OA risk12, was not associated with the 
percentage of the cartilage volume loss in the current analysis (data not shown). For the complete ratio data of 
lateral and medial comparing all the metabolite ratios to the percentage of the cartilage volume loss, please refer 
to the Supplementary Tables 1 and 2.
We next evaluated the correlation between the lysoPC 18:2 to PC 44:3 ratio and two serum biomarkers of 
cartilage degradation, COMP and MMP-1, that were previously assessed in this cohort18. Data showed a weak 
but significant correlation between the lysoPC 18:2 to PC 44:3 ratio and serum COMP levels at both baseline and 
follow-up (both r = 0.32, both p = 0.0002). The ratio was also significantly correlated with serum MMP-1 levels at 
follow-up (r = 0.26, p = 0.002). The significances remained virtually the same after adjustment for age, sex, BMI, 
diabetes, hypertension, dyslipidemia, and treatments taken in the original study.
Metabolic pathway involved in the over-expression of lysoPC 18:2 to PC44:3. The association of 
the higher lysoPC 18:2 to PC44:3 ratio with the percentage of the cartilage volume loss implies that the conversion 
pathway of PC to lysoPC is overactivated in these patients with high cartilage loss. The biochemical conversion 
from PC to lysoPC is mainly catalyzed by lecithin-cholesterol acyltransferase (LCAT) in blood or phospholipase 
A2 (PLA2) in tissues (Fig. 1). In blood, after binding to a lipoprotein, LCAT cleaves the fatty acid in sn-2 position 
of PC which then is trans-esterified to the 3-β-hydroxyl group on the A-ring of cholesterol to form cholesteryl 
ester.
We first examined whether the association between lysoPC 18:2 to PC44:3 ratio and cartilage volume loss 
over time was related to an increased LCAT activity. To this end, the serum LCAT levels were determined in the 
top and bottom 10% of subjects based on the serum lysoPC 18:2 to PC44:3 ratio levels (n = 12 for the bottom 
10% and n = 15 for the top 10%). Although the median value from the patients having the highest ratio was lower 
than those from the lowest one, this did not reach statistical significance (Supplementary Fig. 1), suggesting the 
observed association was not due to differences in LCAT activity.
Next, we evaluated the PLA2 pathway in joint tissues. PLA2 includes several unrelated protein families with 
common enzymatic activity. Previous work examining multiple PLA2 isoforms in chondrocytes suggested 
that four forms of the PLA2, e.g. PLA2G2a, G2d, G4a, and G5, were important in chondrocytes19. We therefore 
Metabolite ratios
Unadjusted* Adjusted**
β (95% CI) P value β (95% CI) P value
PC32:1/PC40:5 0.30 (0.16; 0.44) 2.5*10−5 0.30 (0.16; 0.43) 5.7*10−6
PC32:2/PC40:5 0.21(0.11; 0.30) 5.1*10−5 0.20 (0.11; 0.30) 1.1*10−5
PC42:0/PC40:5 0.26 (0.14; 0.38) 5.4*10−5 0.26 (0.14; 0.38) 7.5*10−6
PC34:1/PC40:5 0.18 (0.09; 0.27) 5.7*10−5 0.19 (0.10; 0.27) 4.5*10−6
Table 3. The top metabolite ratios that associated with the percentage of the medial cartilage volume loss 
at 24 months. *Associations were tested by using linear regression model. **Covariates including age, sex, 
BMI, diabetes, hypertension, dyslipidemia, and treatment were included in the multivariable linear regression 
model. β stands for percentage change in cartilage volume at 24 months per unit increase for a given ratio. PC: 
phosphatidylcholine; first number represents the total number of carbons in the PC and the second number 
stands for the number of the double bonds in the compound.
Figure 1. Biochemical conversion pathways of phosphatidylcholine (PC) to lysophosphatidylcholine (lysoPC). 
*HDL: high density lipoprotein; LCAT: lecithin-cholesterol acyltransferase; PLA2: Phospholipase A2.
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examined these four PLA2 isoforms. We failed to design a primer to capture PLA2G2d but were successful for the 
three other different isoforms of PLA2. Determination was done in three joint tissues, namely cartilage, synovial 
membrane, and subchondral bone. Data showed that in OA the gene expression of PLA2G5, but not the other two 
isoforms, had 85% increased expression compared to controls (p = 6.6*10−5; Fig. 2) in cartilage. Of note, there 
was no difference between knee (n = 9) and hip (n = 23) OA (p = 0.51). PLA2G5 expression was also significantly 
over-expressed by 19% in OA synovial membrane compared to the controls (p = 0.04; Fig. 2). A similar trend was 
also seen in OA subchondral bone, but the difference did not reach statistical significance (Supplementary Fig. 2).
It has been previously reported19 that multiple PLA2 isoform expression in chondrocytes can be stimulated by 
pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Data revealed that IL-6 and TNF-α were strongly 
correlated with PLA2G5 expression (r = 0.63, and r = 0.57, respectively, p ≤ 0.0008; Fig. 3). Although a positive 
correlation was also found for IL-1β (r = 0.27), this did not reach statistical significance. We further looked at the 
correlation between these cytokines in OA cartilage. As expected, they were highly correlated with each other (all 
p ≤ 0.02), the higher correlations of which were found between IL-6 and TNF-α (r = 0.78, p = 1.2*10−7) (Fig. 3). 
Multivariable regression modeling with the three cytokines showed that the IL-6 was the only one remaining to 
be associated with PLA2G5 (β = 0.55; p = 0.018).
Discussion
To the best of our knowledge, this is the first study using a comprehensive metabolic approach to document the 
association between knee OA progression and the activation of the conversion pathway of PC to lysoPC. In this 
study we used metabolite ratios rather than individual metabolite concentrations in the analysis because they are 
not derived from two independent variables but related to each other representing metabolic enzymatic reaction 
in the body. Previous studies have also reported that metabolite ratios serve as good biomarkers with predictive 
ability beyond that of the single constituents because of the reduced noise and increased statistical power20. It has 
been shown that metabolite ratios have stronger and more meaningful association with phenotypes21,22. Further, 
we used the percentage of cartilage volume loss assessed by MRI as the OA disease progression measure, which 
is an objective, quantitative and continuous measure as opposed to pain or symptoms, which used scoring scales 
and are patient-dependent. Moreover, the pain outcome did not reflect the pathological process and is generally 
poorly related to joint tissue structural alterations (refer to the review17).
Emerging data showed that the serum level ratio of lysoPC 18:2 to PC44:3 has a great potential as a new bio-
marker in monitoring knee OA disease progression, in that it was highly associated with cartilage volume loss 
over time in the lateral compartment in symptomatic knee OA patients. Of note, while we can describe the PC 
44:3 as a group of glycerophosphocholine compounds containing 1 ester linked fatty acid and 1 ether linked fatty 
alcohol in their structure, the combined chain length of the fatty alcohol and the fatty acid would be 44 carbon 
atoms, the total number of double bonds including both chains would be 3, owing to the limitation of the method 
we used, the details of the actual structure of this compound remains unknown and an item for further character-
ization using higher resolution methods in future studies.
Interestingly, the lysoPC 18:2 to PC44:3 ratio was also suggested for monitoring anti-inflammatory treatment 
in another arthritic disease, rheumatoid arthritis23. This may suggest that the ratio is a marker to detect active 
cartilage damage regardless what disease causes the damage. However, the sample size was too small in that study 
to draw a firm conclusion. In line with such ratio, previous data from the Dutch CHeCK cohort using a relatively 
small sample size reported that a lysoPC to PC ratio in plasma, the lysoPC with 16 and 18 carbons to PC with 
36 and 38 carbons and four double bonds, has a slightly higher level in early and moderate OA as classified by 
radiography than the control15. While this ratio involved lysoPC and PC with different number of carbons and 
double bonds compared to what we found in the current study, it represents the same conversion pathway of PC 
to lysoPC. Furthermore, our group demonstrated that total lysoPC to PC ratio in plasma was associated not only 
Figure 2. PLA2G5 expression levels in human cartilage and synovial membrane. PLA2G5: Phospholipase A2 
group 5. Log PLA2G5 RQ: Natural logarithm transformed relative quantification of PLA2G5 expression. p values 
were obtained by Student’s t test.
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with knee OA risk but is predictive of total joint replacement surgery over 10-years14. The current study not only 
extended these findings on OA progression, but more specifically identified the conversion of PC with 44 carbons 
and 3 double bonds to lysoPC with 18 carbons and 2 double bonds.
The reason for the association with lateral compartment cartilage volume loss is not clear, but this site was 
also favoured in the association of other serum biomarkers with cartilage volume loss24,25 and assessment of 
disease-modifying OA drugs using MRI16,18,26,27, and likely reflects an association with less advanced OA carti-
lage lesions. Indeed, it is well known that, in symptomatic OA patients, the cartilage alterations are generally less 
severe in the lateral than in the medial compartment. Moreover, and related to our data, the COMP level was 
previously found predominately associated with the loss of cartilage in the lateral compartment18. Interestingly, 
here we showed a strong correlation between the lysoPC 18:2 to PC44:3 ratio and the COMP levels at both base-
line and follow-up.
With the use of a very conservative method to control for multiple comparison, we did not find any associa-
tions between the metabolite ratios and medial compartment cartilage volume loss. However, in this compart-
ment, the top associated metabolite ratios also suggest the involvement of PC metabolic pathway. Since these 
ratios are all related to PCs with different number of carbons but not with lysoPCs, we speculate that this is related 
to PC synthesis rather than its catabolic process. Nevertheless, the findings on the medial compartment warrant 
further investigation in a larger sample size.
It is well known that the conversion of PC to lysoPC is mainly catalyzed by LCAT in blood and PLA2 in tis-
sues28,29. Another emerging finding of the current study is that an over-activation of LCAT activity in blood is 
not the factor responsible, but that a PLA2 isoform, the PLA2G5, in OA tissues appeared to be involved. Hence, 
both OA cartilage and synovial membrane demonstrated a significant increase in this enzyme (PLA2G5), with 
a higher level in cartilage. This is consistent with a previous report suggesting that although in OA articulations 
both cartilage and synovial membrane contain large quantities of PLA2, the cartilage appeared to be a primary 
source of this factor30. Moreover, the finding that the proinflammatory cytokine IL-6 is involved in this enzyme’s 
over-expression in OA cartilage also agrees with studies reporting that proinflammatory cytokines, including 
IL-6, stimulate multiple PLA2 isoenzyme expression in OA chondrocytes19, and that this cytokine level correlated 
with knee OA progression and risk of cartilage loss18,31,32. These also concur with the findings that the lysoPC 18:2 
to PC 44:3 ratio strongly correlated with two well known cartilage degradation biomarkers, COMP and MMP1.
An explanation for the lysoPC 18:2 to PC44:3 ratio being associated with the articular structure degeneration 
could be as follows. One of the consequences of the augmented conversion of PC to lysoPC is the increased lys-
oPC levels. LysoPC, also known as lysolecithin, is a potent membrane-dissolving agent that was reported as one of 
the first truly caspase-derived “find me” signals. It specifically results in the recruitment of phagocytes to the site 
of apoptosis and facilitates opsonization of apoptotic cells33. Chondrocyte apoptosis was significantly associated 
with cartilage damage and pathogenesis of OA34. In addition, lysoPCs, particularly acyl-alkyl phosphatidylcho-
lines, are potential precursors for synthesis of platelet activating factor (PAF), a factor well known to play an 
important role in the inflammatory response and mediation. Although the role of PAF has been demonstrated 
Figure 3. Correlation of three pre-inflammatory cytokines and PLA2G5 in osteoarthritic cartilage tissue. X and 
Y-axes are natural logarithm transformed relative quantification of gene expression. r is Pearson’s correlation 
coefficient. p values were obtained by the exact test. PLA2G5: Phospholipase A2 group 5; TNF-α: Tumor necrosis 
factor alpha; IL-6: Interleukin 6; IL-1β: Interleukin 1 beta.
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in the arthritic disease rheumatoid arthritis and osteoporosis35,36, there is no study on OA pathophysiology. It is 
however possible that PAF, due to its effect on the inflammatory cascade, could play a role in OA. Further studies 
with PAF on OA are warranted.
Another consequence of the conversion of PC to lysoPC is a release of polyunsaturated fatty acids includ-
ing arachidonic acid, linoleic acid, and linolenic acid from the sn-2 position of the PC phospholipid glyceryl 
backbone. These fatty acids are precursors of eicosanoids, prostanoids and endocannabinoids, which are bioac-
tive molecules affecting a variety of physiological processes including inflammatory processes37. Data showed 
that using molecules targeting cyclooxygenase or lipoxygenase alone has no effect on cartilage volume loss38, 
but dual inhibitors did reduce cartilage volume loss16, suggesting multiple bioactive molecules produced by the 
eicosanoid pathway are involved in OA disease progression. In the current study, about half of the patients were 
treated with licofelone, a dual inhibitor of cyclooxygenase and lipoxygenase. Additional experiments revealed 
that although a lower level of the lysoPC18:2 to PC44:3 ratio was found in the licofelone group (−0.31 ± 0.57) 
than in the naproxen group (cyclooxygenase inhibitor; 1.74 ± 9.92), the difference did not reach statistical signif-
icance. Moreover, as the lysoPC18:2 to PC44:3 ratio is associated with cartilage volume loss and the licofelone16 
reduced the cartilage volume loss in the lateral compartment, these both suggest that patients with a lower level 
of the lysoPC18:2 to PC44:3 ratio who would have less cartilage loss over time could benefit from the licofelone 
treatment. This important finding, if confirmed in an independent study, could provide new information about 
this ratio being used as a biomarker to predict drug efficacy on articular structure in clinical trials, at least for 
evaluating therapy looking at such a dual inhibitor treatment. Furthermore, and in line with the use of this ratio 
as a biomarker in clinical trials, this specific PC conversion is likely to produce the bioactive molecule oleoyleth-
anolamide (OEA). A recent study reported that the OEA level was increased twice in the synovial fluid of the OA 
dog knee when compared to the contralateral joints39. However, we did not have data on the OEA in the current 
study, further human studies on OEA in OA are warranted.
This study has some limitations. First, although further studies are required to confirm the finding of the 
association between the lysoPC18:2 to PC 44:3 ratio and cartilage volume loss over time, we are confident of its 
validity. In support of this finding is a post-hoc power calculation that showed that we had 100% study power 
to detect the difference we observed with the sample size and at significance level of 2.3 × 10−6 which we used 
in the study, as well as the data on the expression levels of relevant enzymes involved in this metabolic pathway. 
Caution should be taken in the interpretation of the gene expression results as these were done on the end-stage 
OA patients. Secondly, as mentioned above, the actual structure of PC 44:3 remains unknown. As the metabolic 
profiling was done using Biocrates p180 kits with a triple quad MS, and this assay does not have enough reso-
lution to distinguish compounds with same nominal parent mass and producing same m/z fragment, we could 
not ascertain the details of its structure. Further studies with a higher resolution method are needed for more 
information on this compound. Lastly, while we used very conservative statistical method to reduce the chance 
of false positives, the current study lacks an independent replication which is considered as a gold standard to 
confirm the findings.
In conclusion, our data suggest that the ratio of lysoPC 18:2 to PC44:3 is associated with OA progression and 
warrants further investigation in an independent cohort.
patients and Methods
Individual selection. OA patients. This post hoc study used a cohort from the previously published Phase 
III clinical trial of patients with symptomatic knee OA comparing the effect on cartilage volume loss of oral 
treatment with licofelone, a lipoxygenase/cyclo-oxygenase inhibitor, with naproxen as previously described16. 
The patients (n = 139) selected for the present work were those who completed the study according to protocol 
(ATP)16,18,24, had serum collected at baseline, and MRI performed at baseline and 24 months. Briefly, patients with 
primary symptomatic knee OA of the medial tibiofemoral compartment, diagnosed according to the American 
College of Rheumatology (ACR)40, were recruited from outpatient rheumatology clinics. Patients had a pain level 
of no less than 40 mm on the visual analogue scale, radiographic OA grade 2-3 on the Kellgren-Lawrence scale 
and at least one of the following three risk factors for increased risk of radiographic progression: body mass index 
(BMI) > 30 kg/m2, presence of Heberden’s nodes, or female gender. The original study protocol was approved 
by a central review board (IRB Institutional Review Board Services, Toronto, ON, Canada) and the institutional 
review board of the Centre hospitalier de l’Université de Sherbrooke (Sherbrooke, QC, Canada), and all patients 
gave their oral and written informed consent to participate, including permission for the use of serum to be col-
lected throughout the study for biomarker studies.
Human joint tissue samples. Articular cartilage, subchondral bone, and synovial membrane tissue samples were 
from the biobank of the Newfoundland Osteoarthritis Study (NFOAS) as previously described12. OA joint tissues 
were obtained from total hip or knee joint replacement patients due to primary OA whereas non-OA (control) 
joint tissues were obtained from hemi-arthroplasty of the hip due to fractures of the femoral neck. All the joint 
tissue samples were collected within half an hour of the surgery, flash frozen, and stored in liquid nitrogen for 
later DNA/RNA extraction. Both OA and controls were from the same source population of Newfoundland & 
Labrador (Canada). OA diagnosis was made based on ACR criteria40. Controls were confirmed by their hip X-ray 
data and the pathological examination of the removed femoral head cartilage. A total of 32 OA and 16 control car-
tilage samples, 17 OA and 11 control synovium samples, and 40 OA and 9 control subchondral bone samples were 
included in the study. Non-OA controls were on average older than OA patients (79 ± 10 years vs 64 ± 9 years).
Serum metabolic profiling. Serum samples collected after overnight fasting at baseline was stored in 
−80 °C freezer until analysis. Metabolic profiling on serum was performed using Biocrates AbsoluteIDQ® p180 
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kit, which assesses 186 metabolites including acylcarnitines (n = 40), amino acids (n = 22), biogenic amines 
(n = 18), hexoses (sum of hexoses) (n = 1), and phopho-and sphingolipids (n = 105). The details of the 186 
metabolites are listed in the Supplementary Table 3. The profiling was done using an API4000 Qtrap® tandem 
mass spectrometry instrument (Applied Biosystems/MDS Analytical Technologies, Foster City, CA) equipped 
with Agilent 1100 HPLC system at The Metabolomics Innovation Centre (https://www.metabolomicscentre.ca). 
The complete analytical process (e.g., the targeted metabolite concentration) was performed using the MetIQ 
software package, which is an integral part of the AbsoluteIDQ® kit. Concentrations of all metabolites analysed 
are reported in μM. The complete metabolic profiling method using this kit was as described41. The experimental 
metabolomics measurement technique is describe in detail by US patent US 2007/0004044 and in the manufac-
turer’s manuals (https://www.biocrates.com/images/p180_Folder_HP_v01-2018.pdf). The kit has been used in 
over 800 studies (https://www.biocrates.com/resources1/publications/publications-chronological). Our in-house 
reproducibility of the assay was performed in 23 samples as previously described41. The mean of the coefficient 
of variation (CV) for all the metabolites was 0.07 ± 0.05 and 90% of the metabolites had a CV of less than 0.10.
Lecithin-cholesterol acyltransferase (LCAT) measurement. Serum LCAT was measured by ELISA 
(sensitivity 30 ng/ml; Cell Biolabs Inc., San Diego, California, USA). Measurement was carried out in duplicate for 
each sample in accordance with the manufacturer’s instruction with modification to sample dilution factor (45×) 
and measurement means were used in the analysis.
RNA extraction and real-time PCR. Total RNA for human cartilage, subchondral bone and synovial 
membrane samples was extracted, quantified and treated with DNase as previously described42. mRNA levels of 
PLA2G2a, PLA2G4a, PLA2G5, IL-1β, IL-6, and TNF-α were measured by quantitative PCR method (qPCR) using 
ABI 7900HT Fast Real-Time PCR System on 96-well plate. Complementary DNA (cDNA) synthesis was done 
as described previously42. GAPDH was used as an internal reference gene for data normalization. Primers were 
designed using NCBI primer-blast tool and validated using a 4-point dilution series of pooled cDNA samples. The 
details of the primers are listed in Table 4. qPCR was performed in triplicate using 5 µl of cDNA, 10 µl SYBR Green 
(Power SYBR® Green PCR Master Mix, Applied Biosystems, 4367659), and 0.4 µl of forward and reverse primers 
in a final volume of 20 µl. Cycling conditions were: 95 °C for 10 min, 95 °C for 15 sec, and 60 °C for 1 min, repeated 
in 45 cycles, followed by melt-curve analysis. 7900 SDSv2.4 and RQ Manager were used for data collection and 
analysis. One of the control samples was selected as calibrator, and the relative quantification (RQ) of target genes’ 
mRNA levels was calculated as fold changes in relation to the calibrator using Livak method43.
Magnetic resonance imaging (MRI) and determination of cartilage volume and loss over 
time. High-resolution three-dimensional (3-D) MR images were obtained using 1.5 T with an integrated 
knee coil. These examinations are optimized 3-D FISP acquisitions with water excitation (Siemens, Erlangen, 
Germany) or 3-D SPGR acquisitions with fat suppression (General Electric, Milwaukee, Wisconsin, USA), 
as previously described16. Knee joint cartilage volume at baseline and 24 months was evaluated at the time of 
the original study16. Briefly, cartilage volume of the knee joint was measured using a specially developed com-
puter program (ArthroLab, Montreal, Quebec, Canada) as previously described44,45. Cartilage thickness was 
defined as the Euclidian distance between the bone-cartilage interface defined by the baseline image and the 
cartilage-surrounding tissue interface. It was computed in 3D space for each point of the bone surface along the 
direction perpendicular to the bone surface. Each thickness value measured was expressed as a standardized 
map representation and designated as a thickness map. Global or subregion volumes were evaluated directly 
from offset-maps as the sum of elementary volumes. Elementary volume was defined as the volume between the 
bone-cartilage interface offset-map and its corresponding cartilage-synovium offset-map. Because a patient’s knee 
cannot reliably be placed in the MRI machine in precisely the same position (orientation and flexion) at each visit, 
a registration procedure was done to provide a similar standardized view of the tibia and femur for follow-up 
evaluation over time. Baseline bone-cartilage interfaces were used as a reference. The change in knee cartilage 
volume was obtained by subtracting the follow-up volume from the baseline volume and expressed as a percent-
age of cartilage volume loss. Percentage change was calculated by: (baseline knee cartilage volume – follow-up 
knee cartilage volume/baseline knee cartilage volume) times 100. The change in cartilage volume over time was 
calculated for the medial and lateral compartments (compartment comprising femur and plateau) of the knee. 
Forward primer Sequence (5′ > 3′) Reverse primer Sequence (5′ > 3′)
Amplicon 
Size (bp) R2 Efficiency
GAPDH GCAAATTCCATGGCACCGT TCGCCCCACTTGATTTTGG 106 0.999 94.3~100.8%
PLA2G2a CAACGGATCGCTGCTGTGTC GCCACATCCACGTTTCTCCA 65 0.998 98.6%
PLA2G4a ACAAAGCAGAGGCTCCACAA TTCAGTGCCTTTGGGTTCGT 115 0.992 98.0%
PLA2G5 TCCTGGCTTGTAGTGTGCCT CCGTAGTTTGTCAGGGCGTT 97 0.994 97.5%
IL-1β TGCTCTGGGATTCTCTTCAGC ATTGCCACTGTAATAAGCCATCA 107 0.996 98.3%
IL-6 TGAGGAGACTTGCCTGGTGA CACAGCTCTGGCTTGTTCCT 109 0.997 96.3%
TNF-α ATGTTGTAGCAAACCCTCAAGC TCTCTCAGCTCCACGCCATT 91 0.99 94.3%
Table 4. Primers used in quantitative PCR (qPCR). GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; 
PLA2G2a: Phospholipase A2 group 2a; PLA2G4a: Phospholipase A2 group 4a; PLA2G5: Phospholipase A2 group 
5; IL-1β: Interleukin 1 beta; IL-6: Interleukin 6; TNF-α: Tumor necrosis factor alpha.
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The reproducibility of the method has previously been shown to be excellent; between-reader agreement of meas-
urement had ICCs ranging from 0.958 to 0.997 for global knee cartilage. Test-retest reliability of within-reader 
measurements had Pearson correlation coefficients ranging from 0.978 to 0.99945. The percentage change in car-
tilage volume at 24 months was used as disease progression measures.
Statistical analysis. The following quality control (QC) procedures were applied to the metabolomics data. 
Metabolites were removed for subsequent analysis if more than 10% of the samples had values below the limit 
of detection. Then, missing values were imputed by the mean of the given metabolites. Principal component 
analysis (PCA) was utilized to examine batch effects, which demonstrated that we did not have any batch effect 
in our experiment (Supplementary Fig. 3); therefore, no correction for batch effects was performed. Among the 
186 metabolites, 152 passed the QC procedure and were included in the analysis. The 152 metabolite concentra-
tions were then standardized using the Z-score, 21,952 pair-wise metabolite ratios were calculated as proxies for 
enzymatic reactions and used in the analysis. Also, we have previously found that metabolite ratios rather than 
metabolite concentrations themselves were highly correlated between plasma and synovial fluids46.
Unadjusted analyses were performed to identify metabolite ratio(s) that associated with cartilage volume 
changes and linear regression modeling was utilized to adjust for potential confounding factors including age, 
sex, BMI, and treatment. A metabolome-wide significance level of α = 0.05/21952 = 2.3*10−6 was defined after 
correcting multiple testing with the Bonferroni method. LCAT levels in serum as well as gene expressions were 
compared between OA and controls by Student’s t test, and Pearson correlation (r) was used to examine the cor-
relations between gene expressions. Multivariable regression modeling was also used to examine the independent 
correlation between these gene expression and PLA2. Unadjusted or adjusted 95% confidence intervals (95% 
CIs) were provided where appropriate. All the analyses were done in R version 3.4.3 with built in functions for 
linear regression, Student’s t test, and Pearson correlation coefficient. Visualizations of the results were done with 
ggplot2 R package47.
Ethics approval and consent for patients to participate. The original study protocol was approved 
by a central review board (IRB Institutional Review Board Services, Toronto, ON, Canada) and the institutional 
review board of the Centre hospitalier de l’Université Sherbrooke (Sherbrooke, QC, Canada). The original trial 
was conducted in compliance with the ethical principles that have their origin in the Declaration of Helsinki 
(2000) and are consistent with the “Good Clinical Practice” ICH Tripartite Guideline (January 1997) and the 
applicable laws and regulations of Canada, whichever afforded the greater protection to the individual. Ethical 
approval for this post hoc study was obtained with the original study, thus further approval was not required. All 
patients provided informed consent.
Data Availability
Data described in the manuscript is available to readers upon the request.
References
 1. The burden of musculoskeletal conditions at the start of the new millennium: report of a WHO Scientific Group. (World Health 
Organisation, Geneva, 2003).
 2. Vos, T. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 380, 2163–2196 (2012).
 3. Hiligsmann, M. et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for 
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 43, 303–313 (2013).
 4. Bingham, C. O. III. et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or 
slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational 
knee osteoarthritis structural arthritis study. Arthritis Rheum 54, 3494–3507 (2006).
 5. Leyland, K. M. et al. The natural history of radiographic knee osteoarthritis: a fourteen-year population-based cohort study. Arthritis 
Rheum 64, 2243–2251 (2012).
 6. Raynauld, J. P. et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and 
correlation with clinical symptoms and radiologic changes. Arthritis Rheum 50, 476–487 (2004).
 7. Zhai, G., Randell, E. W. & Rahman, P. Metabolomics of osteoarthritis: emerging novel markers and their potential clinical utility. 
Rheumatology (Oxford) 57, 2087–2095 (2018).
 8. Mickiewicz, B. et al. Metabolic analysis of knee synovial fluid as a potential diagnostic approach for osteoarthritis. J Orthop Res 33, 
1631–1638 (2015).
 9. Zheng, K. et al. Global and targeted metabolomics of synovial fluid discovers special osteoarthritis metabolites. J Orthop Res 35, 
1973–1981 (2017).
 10. Xu, Z. et al. Cartilaginous Metabolomic Study Reveals Potential Mechanisms of Osteophyte Formation in Osteoarthritis. J Proteome 
Res 16, 1425–1435 (2017).
 11. Carlson, A. K. et al. Application of global metabolomic profiling of synovial fluid for osteoarthritis biomarkers. Biochem Biophys Res 
Commun 499, 182–188 (2018).
 12. Zhang, W. et al. Metabolomic analysis of human plasma reveals that arginine is depleted in knee osteoarthritis patients. Osteoarthritis 
Cartilage 24, 827–834 (2016).
 13. Pascale, V. et al. L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in plasma and synovial fluid of patients 
with knee osteoarthritis. Med Sci Monit 19, 1057–1062 (2013).
 14. Zhang, W. et al. Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis. Rheumatology 
(Oxford) 55, 1566–1574 (2016).
 15. Castro-Perez, J. M. et al. Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker 
detection and identification in osteoarthritis patients. J Proteome Res 9, 2377–2389 (2010).
 16. Raynauld, J. P. et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss 
in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 68, 938–947 (2009).
 17. Pelletier, J. P. et al. What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann 
Rheum Dis 72, 1594–1604 (2013).
9Scientific RepoRts |          (2019) 9:9648  | https://doi.org/10.1038/s41598-019-46185-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 18. Pelletier, J. P. et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis 
drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 69, 2095–2101 (2010).
 19. Leistad, L., Feuerherm, A. J., Faxvaag, A. & Johansen, B. Multiple phospholipase A2 enzymes participate in the inflammatory process 
in osteoarthritic cartilage. Scand J Rheumatol 40, 308–316 (2011).
 20. Petersen, A. K. et al. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. 
BMC Bioinformatics 13, 120, https://doi.org/10.1186/1471-2105-13-120 (2012).
 21. Heemskerk, M. M., van Harmelen, V. J., van Dijk, K. W. & van Klinken, J. B. Reanalysis of mGWAS results and in vitro validation 
show that lactate dehydrogenase interacts with branched-chain amino acid metabolism. Eur J Hum Genet 24, 142–145 (2016).
 22. Molnos, S. et al. Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. Diabetologia 61, 117–129 (2018).
 23. Fuchs, B., Schiller, J., Wagner, U., Hantzschel, H. & Arnold, K. The phosphatidylcholine/lysophosphatidylcholine ratio in human 
plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 38, 
925–933 (2005).
 24. Martel-Pelletier, J., Raynauld, J. P., Dorais, M., Abram, F. & Pelletier, J. P. The levels of the adipokines adipsin and leptin are associated 
with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis 
patients: a post hoc analysis. Rheumatology (Oxford) 55, 680–688 (2016).
 25. Valverde-Franco, G. et al. High in vivo levels of adipsin lead to increased knee tissue degradation in osteoarthritis: data from humans 
and animal models. Rheumatology (Oxford) 57, 1851–1860 (2018).
 26. Wildi, L. M. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients 
starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann 
Rheum Dis 70, 982–989 (2011).
 27. Martel-Pelletier, J. et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 
24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 74, 547–556 (2015).
 28. Lambeau, G. & Gelb, M. H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77, 
495–520 (2008).
 29. Sorci-Thomas, M., Kearns, M. W. & Lee, J. P. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. 
Structure:function relationships. J Biol Chem 268, 21403–21409 (1993).
 30. Pruzanski, W., Bogoch, E., Stefanski, E., Wloch, M. & Vadas, P. Enzymatic activity and distribution of phospholipase A2 in human 
cartilage. Life Sci 48, 2457–2462 (1991).
 31. Livshits, G. et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study. Arthritis Rheum 
60, 2037–2045 (2009).
 32. Ayral, X., Pickering, E. H., Woodworth, T. G., Mackillop, N. & Dougados, M. Synovitis: a potential predictive factor of structural 
progression of medial tibiofemoral knee osteoarthritis–results of a 1 year longitudinal arthroscopic study in 422 patients. 
Osteoarthritis Cartilage 13, 361–367 (2005).
 33. Lauber, K. et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113, 
717–730 (2003).
 34. Hwang, H. S. & Kim, H. A. Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis. Int J Mol Sci 16, 26035–26054 (2015).
 35. Edwards, L. J. & Constantinescu, C. S. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic 
target in autoimmune diseases. Inflamm Allergy Drug Targets 8, 182–190 (2009).
 36. Hikiji, H., Ishii, S., Shindou, H., Takato, T. & Shimizu, T. Absence of platelet-activating factor receptor protects mice from 
osteoporosis following ovariectomy. J Clin Invest 114, 85–93 (2004).
 37. Astudillo, A. M., Balgoma, D., Balboa, M. A. & Balsinde, J. Dynamics of arachidonic acid mobilization by inflammatory cells. 
Biochim Biophys Acta 1821, 249–256 (2012).
 38. Raynauld, J. P. et al. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect 
of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum 40, 
185–192 (2010).
 39. Valastro, C. et al. Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with 
osteoarthritis: a pilot study. BMC Vet Res 13, 309 (2017).
 40. Altman, R. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the 
knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis and rheumatism 29, 
1039–1049 (1986).
 41. Zhai, G. et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann 
Rheum Dis 69, 1227–1231 (2010).
 42. Aref-Eshghi, E. et al. Overexpression of MMP13 in human osteoarthritic cartilage is associated with the SMAD-independent TGF-
beta signalling pathway. Arthritis Res Ther 17, 264, https://doi.org/10.1186/s13075-015-0788-x (2015).
 43. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408 (2001).
 44. Kauffmann, C. et al. Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation 
study using a synthetic model. IEEE Trans Biomed Eng 50, 978–988 (2003).
 45. Raynauld, J. P. et al. Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness 
and volume in human normal and osteoarthritic knees. Osteoarthritis Cartilage 11, 351–360 (2003).
 46. Zhang, W. et al. Relationship Between Blood Plasma and Synovial Fluid Metabolite Concentrations in Patients with Osteoarthritis. 
J Rheumatol 42, 859–865 (2015).
 47. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer, 2009).
Acknowledgements
We thank all the study participants who made this study possible. Metabolic profiling was done at The 
Metabolomics Innovation Centre (TMIC). The study was supported by the Canadian Institutes of Health 
Research (CIHR). The original trial was supported in part by grants from Merckle GmbH (Ulm, Germany) 
and ArthroLab Inc. (Montréal, QC, Canada). The funding sources did not have any role in the study design, 
collection, analysis and interpretation of data.
Author Contributions
The conception and design of the study (G.Z., J.M.P.), acquisition of data (G.Z., M.L., J.P.P., D.A., E.R., P.R., G.J., 
J.M.P.), analysis (G.Z.), and interpretation of data (G.Z., M.L., J.P.P., D.A., E.R., P.R., G.J., J.M.P.). Drafting the 
article (G.Z., J.M.P.), and revising it critically for important intellectura content (M.L., J.P.P., D.A., E.R., P.R., G.J., 
J.M.P.). Final approval of the version to be submitted (G.Z., M.L., J.P.P., D.A., E.R., P.R., G.J., J.M.P.).
1 0Scientific RepoRts |          (2019) 9:9648  | https://doi.org/10.1038/s41598-019-46185-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46185-w.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
